Answers are grounded in this paper and cite their sources.
Persistent human immunodeficiency virus type 1 (HIV-1) latency remains a major barrier to durable remission, yet the host pathways that regulate proviral transcriptional competence and inducible reactivation remain incompletely defined. Thioredoxin-interacting protein (TXNIP) is a glucose-responsive host factor, but its role in HIV-1 transcription and latency regulation has not been established. Here, we provide evidence that TXNIP supports HIV-1 long terminal repeat (LTR)-driven transcription, productive replication, and latency reversal. Genetic depletion of TXNIP reduced LTR reporter activity, nascent viral transcripts, virus production, and latency-reversing agent (LRA)-induced reactivation across reporter-based, productive-infection, chronically infected, latency, primary-cell, and ex vivo models, whereas TXNIP overexpression enhanced viral transcriptional output. Chromatin immunoprecipitation (ChIP) further detected TXNIP-associated signals at HIV-1 LTR-containing chromatin in both TZM-bl and Jurkat T-cell contexts, and co-immunoprecipitation (Co-IP) analyses showed that TXNIP associates with BRD4-, CDK9-, and Tat-containing transcriptional complexes, consistent with a cofactor-associated model of TXNIP-linked HIV-1 transcriptional regulation. Mechanistically, our data support an enhancer of zeste homolog 2 (EZH2)-ETS variant transcription factor 1 (ETV1)-TXNIP regulatory axis linking epigenetic repression to HIV-1 transcriptional control. Genetic EZH2 perturbation and pharmacological perturbation of EZH2-associated repression reduced histone H3 lysine 27 trimethylation (H3K27me3) enrichment at the ETV1 promoter, increased ETV1 expression, and enhanced TXNIP promoter activity. ChIP-qPCR and promoter-reporter analyses supported an ETV1-associated regulatory link between EZH2-associated repression and TXNIP expression. Pharmacological perturbation with SRI-37330 suppressed HIV-1 replication, nascent transcription, and inducible reactivation, including in ex vivo CD4 + T cells from antiretroviral therapy (ART)-suppressed individuals; this inhibitory effect was attenuated in TXNIP-depleted cells. Together, these findings identify TXNIP as a host determinant of HIV-1 transcriptional competence and support an EZH2-ETV1-TXNIP regulatory pathway that links epigenetic regulation of TXNIP expression to HIV-1 transcriptional control.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: